MILWAUKEE, May 24, 2022 /PRNewswire/ -- Ademi LLP is investigating Entasis (Nasdaq: ETTX) for possible breaches of fiduciary duty and other violations of law in its transaction with Innoviva. 

Click here to learn how to join the action: https://www.ademilaw.com/case/entasis-therapeutics-holdings-inc or call Guri Ademi toll-free at 866-264-3995.  There is no cost or obligation to you.

Ademi LLP alleges Entasis' financial outlook and prospects are excellent and yet Entasis holders will receive only $2.20 per share in an all-cash transaction. The transaction agreement unreasonably limits competing bids for Entasis by prohibiting solicitation of further bids, and imposing a significant penalty if Entasis accepts a superior bid. Entasis insiders will receive substantial benefits as part of change of control arrangements.

We are investigating the conduct of Entasis' board of directors, and whether they are (i) fulfilling their fiduciary duties to all shareholders, and (ii) obtaining a fair and reasonable price for Entasis.

If you own Entasis common stock and wish to obtain additional information, please contact Guri Ademi either at [email protected] or toll-free: 866-264-3995, or https://www.ademilaw.com/case/entasis-therapeutics-holdings-inc.                       

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts

Ademi LLP                                                          
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001

View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-ademi-llp-investigates-whether-entasis-therapeutics-holdings-inc-has-obtained-a-fair-price-in-its-transaction-with-innoviva-301553884.html

SOURCE Ademi LLP